跳至主要内容
临床试验/NCT00002069
NCT00002069已完成不适用

A Study of DTC in Patients With AIDS and AIDS Related Complex

Merieux Institute16 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
试验地点
16

研究概览

简要总结

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Concurrent Medication:
  • Zidovudine (AZT).

排除标准

  • Co-existing Condition:
  • Patients with the following are excluded:
  • Active opportunistic infection or progressive Kaposi's sarcoma (KS).
  • Dementia.
  • Lymphoma.
  • Concurrent Medication:
  • Excluded within 3 weeks of study entry:
  • Other experimental AIDS therapy.
  • Patients with the following are excluded:
  • Active opportunistic infection or progressive Kaposi's sarcoma (KS).
  • Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

研究者

发起方
Merieux Institute
申办方类型
Industry

研究点 (16)

Loading locations...

相似试验